OptiNose (United States)

Recent papers from OptiNose (United States)

1. Efficacy of Exhalation Delivery System With Fluticasone in Chronic Rhinosinusitis With Versus Without PolypsOtolaryngology · 2026
2. EDS‐FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trialsInternational Forum of Allergy & Rhinology · 2024
3. Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)The Journal of Allergy and Clinical Immunology In Practice · 2024
4. Development of computational fluid dynamics methodology for characterization of exhalation delivery system performance in a nasal airway with Draf-III surgeryJournal of Aerosol Science · 2022
5. Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgeryInternational Forum of Allergy & Rhinology · 2022
6. The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal PolypsEar Nose & Throat Journal · 2022
7. Evaluation of the ocular safety associated with the exhalation delivery system with fluticasoneAllergy and Asthma Proceedings · 2021
8. Role of Nasal Casts for In Vitro Evaluation of Nasal Drug Delivery and Quantitative Evaluation of Various Nasal CastsTherapeutic Delivery · 2020
9. Exhalation delivery system with fluticasone improves quality of life and health status: pooled analysis of phase 3 trials NAVIGATE I and IIInternational Forum of Allergy & Rhinology · 2020
10. EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polypsRhinology Journal · 2019
11. Deposition of drugs in the nose and sinuses with an exhalation delivery system vs conventional nasal spray or high-volume irrigation in Draf II/III post-surgical anatomyRhinology Journal · 2019
12. A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational AerosolClinical Therapeutics · 2019
13. A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitisAllergy and Asthma Proceedings · 2018
14. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal PolypsAmerican Journal of Rhinology and Allergy · 2018
15. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposisJournal of Allergy and Clinical Immunology · 2018
16. EXHANCE‐12: 1‐year study of the exhalation delivery system with fluticasone (EDS‐FLU) in chronic rhinosinusitisInternational Forum of Allergy & Rhinology · 2018
17. Saliva oxytocin measures do not reflect peripheral plasma concentrations after intranasal oxytocin administration in men2018
18. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP‐825 Breath Powered ® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral SumatriptanHeadache The Journal of Head and Face Pain · 2017
19. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trialPsychoneuroendocrinology · 2016
20. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessmentTranslational Psychiatry · 2015